Agbonesa, Mark Jay T.

HRN: 21-32-49  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/11/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
05/11/2022
05/17/2022
IVT
115mg
Q8
ALL
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Bloodstream    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: